Antibodies Specific to Pyroglutamated Abeta
AssigneeH. Lundbeck A/S
InventorsSøren Christensen, Lone Helboe
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies specific for pyroglutamated Aβ, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands Further, is provided pyroglutamated N-terminal fragments of murine or human Aβ to generate antibodies and for use m therapeutic purposes
Claims18
An antibody, or a fragment thereof, wherein said antibody and said fragment are capable of specifically binding human AβpE3 with a binding affinity (KD) of about 100 nM to about 5 nM for the human pyroglutamated Aβ fragment pEFRHDSGYE, wherein said antibody comprises:
- (a) a heavy chain variable region (VH) CDR1 comprising GYTFTDYYX1N;
- (b) a heavy chain variable region (VH) CDR2 comprising WX2X3PGSGNX4KYNEKFKG;
- (c) a heavy chain variable region (VH) CDR3 comprising EGX5X6X7Y;
- (d) a light chain variable region (VL) CDR1 comprising KSSQSLLX8SNGX9X10YLN;
- (e) a light chain variable region (VL) CDR2 comprising X11VSKLDS;
- and
- (f) a light chain variable region (VL) CDR3 comprising VQGTHX12PFT;
- wherein X1 to X12 symbolizes a natural amino acid.
An antibody, or a fragment thereof, wherein said antibody and said fragment are capable of specifically binding human AβpE3 with a binding affinity (KD) of about 100 nM to about 5 nM for the human pyroglutamated Aβ fragment pEFRHDSGYE, wherein said antibody comprises a variant of:
- (a) a heavy chain variable region (VH) CDR1 comprising SEQ ID NO:12;
- (b) a heavy chain variable region (VH) CDR2 comprising SEQ ID NO:13;
- (c) a heavy chain variable region (VH) CDR3 comprising SEQ ID NO:14;
- (d) a light chain variable region (VL) CDR1 comprising SEQ ID NO:15;
- (e) a light chain variable region (VL) CDR2 comprising SEQ ID NO:16;
- and
- (f) a light chain variable region (VL) CDR3 comprising SEQ ID NO:17;
- said variant having no more than 4 amino acid differences from said sequences (a)-(f).
An antibody, or a fragment thereof, wherein said antibody and said fragment are capable of specifically binding human AβpE3 with a binding affinity (KD) of about 100 nM to about 5 nM for the human pyroglutamated Aβ fragment pEFRHDSGYE, wherein said antibody comprises a variant of:
- (a) a heavy chain variable region (VH) CDR1 comprising SEQ ID NO:18;
- (b) a heavy chain variable region (VH) CDR2 comprising SEQ ID NO:19;
- (c) a heavy chain variable region (VH) CDR3 comprising SEQ ID NO:20;
- (d) a light chain variable region (VL) CDR1 comprising SEQ ID NO:21;
- (e) a light chain variable region (VL) CDR2 comprising SEQ ID NO:22;
- and
- (f) a light chain variable region (VL) CDR3 comprising SEQ ID NO:23.
- said variant having no more than 4 amino acid differences from said sequences (a)-(f).
18-49. (canceled)
Dependencies are inferred from the claim text.